Talking KRAS-Targeted Therapy in NSCLC With Dr. Riess
Season 3, Episode 24, Jul 27, 2020, 07:00 PM
In our exclusive interview, Dr. Riess discussed the excitement surrounding KRAS G12C inhibitors in NSCLC, preliminary efficacy and safety data with AMG 510, and additional research regarding co-mutations and combinations that could lead to further refinement of the potential role of the agent in the landscape.